Synopsis
Synopsis
0
JDMF
0
KDMF
0
VMF
0
API
0
FDF
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Annual Reports
NA
Finished Drug Prices
NA
1. 5,5-dimethyl-3-(4-nitro-3-(trifluoromethyl)phenyl)- 2,4-imidazolidinedione
2. Anandron
3. Nilandron
4. Ru 23908
5. Ru 23908-10
6. Ru-23908
1. 63612-50-0
2. Anandron
3. Nilandron
4. 5,5-dimethyl-3-(4-nitro-3-(trifluoromethyl)phenyl)imidazolidine-2,4-dione
5. Ru-23908
6. Nilutamida
7. Nilutamidum
8. 5,5-dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl]imidazolidine-2,4-dione
9. Ru 23908
10. 5,5-dimethyl-3-(alpha,alpha,alpha-trifluoro-4-nitro-m-tolyl)hydantoin
11. Nilandrone
12. Nilandron;ru 23908
13. Nsc-758683
14. Chembl1274
15. Chebi:7573
16. Nilutamidum [latin]
17. Nilutamida [spanish]
18. 2,4-imidazolidinedione,5,5-dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl]-
19. 5,5-dimethyl-3-(4-nitro-3-(trifluoromethyl)phenyl)-2,4-imidazolidinedione
20. 5,5-dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl]-2,4-imidazolidinedione
21. 2,4-imidazolidinedione, 5,5-dimethyl-3-(4-nitro-3-(trifluoromethyl)phenyl)-
22. 51g6i8b902
23. Ncgc00015754-08
24. Cas-63612-50-0
25. Dsstox_cid_14165
26. Dsstox_rid_79118
27. Dsstox_gsid_34165
28. Nilutamide [usan:inn:ban]
29. 5,5-dimethyl-3-(4-nitro-3-(trifluoromethyl)-phenyl)imidazolidine-2,4-dione
30. Nilandron (tn)
31. Ru 23908-10
32. Sr-01000076034
33. Nilutamide (usan/inn)
34. Brn 0841906
35. Unii-51g6i8b902
36. Nilutamide, Solid
37. 2,4-imidazolidinedione, 5,5-dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl]-
38. 1-(3'-trifluoromethyl-4'-nitrophenyl)-4,4-dimethylimidazolidine-2,5-dione
39. Mfcd00864670
40. Spectrum_001625
41. Tocris-1759
42. Nilutamide [mi]
43. Specplus_000902
44. Nilutamide [inn]
45. Prestwick0_000928
46. Prestwick1_000928
47. Prestwick2_000928
48. Prestwick3_000928
49. Spectrum2_001973
50. Spectrum3_001633
51. Spectrum4_000600
52. Spectrum5_001512
53. Lopac-n-8534
54. Nilutamide [usan]
55. Nilutamide [vandf]
56. N 8534
57. Nilutamide [mart.]
58. Nilutamide [usp-rs]
59. Nilutamide [who-dd]
60. Bidd:pxr0177
61. Lopac0_000879
62. Schembl12670
63. Bspbio_000836
64. Bspbio_003325
65. Kbiogr_001100
66. Kbioss_002105
67. Mls002154066
68. Bidd:gt0683
69. Divk1c_006998
70. Spectrum1504152
71. Spbio_002125
72. Spbio_003015
73. Bpbio1_000920
74. Gtpl2864
75. Dtxsid3034165
76. Nilutamide [orange Book]
77. Kbio1_001942
78. Kbio2_002105
79. Kbio2_004673
80. Kbio2_007241
81. Kbio3_002545
82. Nilutamide [ep Monograph]
83. Bcpp000148
84. Hms1570j18
85. Hms1922f03
86. Hms2093a10
87. Hms2097j18
88. Hms2230e03
89. Hms3262p19
90. Hms3268c18
91. Hms3369i02
92. Hms3414n15
93. Hms3678n13
94. Hms3714j18
95. Nilutamide [usp Monograph]
96. Pharmakon1600-01504152
97. Amy32529
98. Bcp26617
99. Zinc3874498
100. Tox21 110213
101. Tox21_110213
102. Tox21_301589
103. Tox21_500879
104. Bdbm50135912
105. Ccg-39427
106. Nsc758683
107. S4836
108. Stk633161
109. Akos005565152
110. Akos025147305
111. Tox21_110213_1
112. Ac-5260
113. Bcp9000990
114. Db00665
115. Lp00879
116. Nsc 758683
117. Ru23908
118. Sb19036
119. Sdccgsbi-0050854.p004
120. 5,5-dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl]-1,3-diazolidine-2,4-dione
121. Ncgc00015754-01
122. Ncgc00015754-02
123. Ncgc00015754-03
124. Ncgc00015754-04
125. Ncgc00015754-05
126. Ncgc00015754-06
127. Ncgc00015754-07
128. Ncgc00015754-09
129. Ncgc00015754-10
130. Ncgc00015754-11
131. Ncgc00015754-12
132. Ncgc00015754-15
133. Ncgc00015754-16
134. Ncgc00015754-22
135. Ncgc00025280-01
136. Ncgc00025280-02
137. Ncgc00025280-03
138. Ncgc00025280-04
139. Ncgc00025280-05
140. Ncgc00025280-06
141. Ncgc00025280-07
142. Ncgc00025280-08
143. Ncgc00255271-01
144. Ncgc00261564-01
145. As-14123
146. Bn166184
147. Hy-13702
148. Smr001233381
149. Sbi-0050854.p003
150. Ab00053180
151. Cs-0007719
152. Eu-0100879
153. Ft-0630740
154. N1212
155. C08164
156. D00965
157. Ab00053180_07
158. 612n500
159. A834440
160. L000759
161. Q3877030
162. Ru-23908;ru 23908;ru23908
163. Sr-01000076034-1
164. Sr-01000076034-3
165. Sr-01000076034-5
166. Sr-01000076034-6
167. Sr-01000076034-9
168. Brd-k23566484-001-05-2
169. Brd-k23566484-001-09-4
170. Z2417927201
171. Nilutamide, European Pharmacopoeia (ep) Reference Standard
172. 1-(3'-trifluoromethyl-4'-nitrophenyl)-4,4-dimethyl-imidazoline-2,5-dione
173. 1-(3'-trifluoromethyl-4'-nitrophenyl)4,4-dimethyl-imidazoline-2,5-dione
174. 1-(3'-trifluoromethyl-4'nitrophenyl)-4,4-dimethyl-imidazoline-2,5-dione
175. 1-(3'trifluoromethyl-4'-nitropheyl)-4,4-dimethyl-imidazoline-2,5-dione
176. 1-(3-'trifluoromethyl-4'-nitrophenyl)-4,4-dimethyl-imidazoline-2,5-dione
177. 1-(3-trifluoromethyl-4-nitro-phenyl)-4,4-dimethyl Imidazolidine-2,5-dione
178. 1-(3-trifluoromethyl-4-nitro-phenyl)-4,4-dimethyl-imidazolidine-2,5-dione
179. 1-(3-trifluoromethyl-4-nitro-phenyl)-4,4-dimethyl-imidazoline-2,5-dione
180. 1-(3-trifluoromethyl-4-nitrophenyl)-4,4-dimethyl-imidazoline-2,5-dione
181. 3-(3-(trifluoromethyl)-4-nitrophenyl)-5,5-dimethylimidazolidine-2,4-dione
182. 5,5-dimethyl-3-(4-nitro-3-trifluoromethyl-phenyl)-imidazolidine-2,4-dione
183. Diethyl1,4-dihydro-2,6-dimethyl-1,4-diphenyl-3,5-pyridinedicarboxylate
184. 5,5-dimethyl-3-(.alpha.,.alpha.,.alpha.-trifluoro-4-nitro-m-tolyl)hydantoin
185. 5,5-dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl]-imidazolidine-2,4-dione
Molecular Weight | 317.22 g/mol |
---|---|
Molecular Formula | C12H10F3N3O4 |
XLogP3 | 2 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 7 |
Rotatable Bond Count | 1 |
Exact Mass | 317.06234029 g/mol |
Monoisotopic Mass | 317.06234029 g/mol |
Topological Polar Surface Area | 95.2 Ų |
Heavy Atom Count | 22 |
Formal Charge | 0 |
Complexity | 515 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
1 of 2 | |
---|---|
Drug Name | Nilandron |
PubMed Health | Nilutamide (By mouth) |
Drug Classes | Antiandrogen |
Drug Label | NILANDRON tablets contain nilutamide, a nonsteroidal, orally active antiandrogen having the chemical name 5,5-dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl]-2,4-imidazolidinedione with the following structural formula:Nilutamide is a microcrystalli... |
Active Ingredient | Nilutamide |
Dosage Form | Tablet |
Route | Oral |
Strength | 150mg |
Market Status | Prescription |
Company | Covis Pharma Sarl |
2 of 2 | |
---|---|
Drug Name | Nilandron |
PubMed Health | Nilutamide (By mouth) |
Drug Classes | Antiandrogen |
Drug Label | NILANDRON tablets contain nilutamide, a nonsteroidal, orally active antiandrogen having the chemical name 5,5-dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl]-2,4-imidazolidinedione with the following structural formula:Nilutamide is a microcrystalli... |
Active Ingredient | Nilutamide |
Dosage Form | Tablet |
Route | Oral |
Strength | 150mg |
Market Status | Prescription |
Company | Covis Pharma Sarl |
For use in combination with surgical castration for the treatment of metastatic prostate cancer involving distant lymph nodes, bone, or visceral organs (Stage D2).
FDA Label
Nilutamide is an antineoplastic hormonal agent primarily used in the treatment of prostate cancer. Nilutamide is a pure, nonsteroidal anti-androgen with affinity for androgen receptors (but not for progestogen, estrogen, or glucocorticoid receptors). Consequently, Nilutamide blocks the action of androgens of adrenal and testicular origin that stimulate the growth of normal and malignant prostatic tissue. Prostate cancer is mostly androgen-dependent and can be treated with surgical or chemical castration. To date, antiandrogen monotherapy has not consistently been shown to be equivalent to castration. The relative binding affinity of nilutamide at the androgen receptor is less than that of bicalutamide, but similar to that of hydroxuflutamide.
Antineoplastic Agents
Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)
Androgen Antagonists
Compounds which inhibit or antagonize the biosynthesis or actions of androgens. (See all compounds classified as Androgen Antagonists.)
L - Antineoplastic and immunomodulating agents
L02 - Endocrine therapy
L02B - Hormone antagonists and related agents
L02BB - Anti-androgens
L02BB02 - Nilutamide
Absorption
Rapidly and completely absorbed, yielding high and persistent plasma concentrations.
Route of Elimination
Nilutamide is extensively metabolized andless than 2% of the drug is excreted unchanged in urine after 5 days. Fecal elimination is negligible, ranging from 1.4% to 7% of the dose after 4 to 5 days.
The results of a human metabolism study using 14C-radiolabelled tablets show that nilutamide is extensively metabolized and less than 2% of the drug is excreted unchanged in urine after 5 days.
38.0-59.1 hours
Nilutamide competes with androgen for the binding of androgen receptors, consequently blocking the action of androgens of adrenal and testicular origin that stimulate the growth of normal and malignant prostatic tissue. This blockade of androgen receptors may result in growth arrest or transient tumor regression through inhibition of androgen-dependent DNA and protein synthesis.
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Related Excipient Companies
Excipients by Applications
Global Sales Information
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Nilandron manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Nilandron, including repackagers and relabelers. The FDA regulates Nilandron manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Nilandron API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Nilandron manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Nilandron supplier is an individual or a company that provides Nilandron active pharmaceutical ingredient (API) or Nilandron finished formulations upon request. The Nilandron suppliers may include Nilandron API manufacturers, exporters, distributors and traders.
click here to find a list of Nilandron suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Nilandron DMF (Drug Master File) is a document detailing the whole manufacturing process of Nilandron active pharmaceutical ingredient (API) in detail. Different forms of Nilandron DMFs exist exist since differing nations have different regulations, such as Nilandron USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Nilandron DMF submitted to regulatory agencies in the US is known as a USDMF. Nilandron USDMF includes data on Nilandron's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Nilandron USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Nilandron suppliers with USDMF on PharmaCompass.
A Nilandron CEP of the European Pharmacopoeia monograph is often referred to as a Nilandron Certificate of Suitability (COS). The purpose of a Nilandron CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Nilandron EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Nilandron to their clients by showing that a Nilandron CEP has been issued for it. The manufacturer submits a Nilandron CEP (COS) as part of the market authorization procedure, and it takes on the role of a Nilandron CEP holder for the record. Additionally, the data presented in the Nilandron CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Nilandron DMF.
A Nilandron CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Nilandron CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Nilandron suppliers with CEP (COS) on PharmaCompass.
A Nilandron written confirmation (Nilandron WC) is an official document issued by a regulatory agency to a Nilandron manufacturer, verifying that the manufacturing facility of a Nilandron active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Nilandron APIs or Nilandron finished pharmaceutical products to another nation, regulatory agencies frequently require a Nilandron WC (written confirmation) as part of the regulatory process.
click here to find a list of Nilandron suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Nilandron as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Nilandron API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Nilandron as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Nilandron and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Nilandron NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Nilandron suppliers with NDC on PharmaCompass.
Nilandron Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Nilandron GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Nilandron GMP manufacturer or Nilandron GMP API supplier for your needs.
A Nilandron CoA (Certificate of Analysis) is a formal document that attests to Nilandron's compliance with Nilandron specifications and serves as a tool for batch-level quality control.
Nilandron CoA mostly includes findings from lab analyses of a specific batch. For each Nilandron CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Nilandron may be tested according to a variety of international standards, such as European Pharmacopoeia (Nilandron EP), Nilandron JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Nilandron USP).
LOOKING FOR A SUPPLIER?